8-K

 UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 

Date of report (Date of earliest event reported): December 14, 2012

CHINA JO-JO DRUGSTORES, INC.

(Exact name of registrant as specified in its charter)

Nevada	001-34711	98-0557852
(State or other jurisdiction of incorporation)	(Commission File No.)	(IRS Employer Identification No.)

Room 507-513, 5th Floor, A Building, Meidu Plaza Gongshu District, Hangzhou, Zhejiang Province People’s Republic of China
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number,including area code +86 (571) 88077078

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Item 8.01 Other Events.

On December 14, 2012, the registrant received a letter from The NASDAQ Stock Market LLC (“NASDAQ”) notifying the registrant that it had regained compliance with NASDAQ Listing Rule 5550(a)(2), as the closing bid price of the Company’s common stock had been at or above $1.00 per share for at least 10 consecutive trading days.  The letter further stated that this matter, which had been previously communicated to the Company in NASDAQ’s noncompliance notice dated August 31, 2012 (and which the registrant disclosed in its Current Report on Form 8-K filed with the Securities and Exchange Commission on September 6, 2012), is now closed.

On December 14, 2012, the registrant issued a press release announcing its receipt of the letter. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statement and Exhibits.

(d) EXHIBITS

Exhibit Number	Description
99.1	Press release dated December 14, 2012.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		CHINA JO-JO DRUGSTORES, INC.
Date:	December 14, 2012	(Registrant)
		By:	/s/ Ming Zhao
			Ming Zhao
			Chief Financial Officer

EX-99.1

Exhibit 99.1

China Jo-Jo Drugstores, Inc. Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement

HANGZHOU, China--(BUSINESS WIRE)--China Jo-Jo Drugstores, Inc. (NASDAQ:CJJD) (the “Company”), a retail and wholesale distributor of pharmaceutical and other healthcare products in China, today announced that The NASDAQ Stock Market LLC (“NASDAQ”) notified the Company in a letter dated December 14, 2012, that it has regained full compliance with the NASDAQ Capital Market’s minimum bid price requirement for continued listing.

The letter notes that as of December 13, 2012, the Company’s common stock evidenced a closing bid price at or in excess of the $1.00 minimum requirement for at least ten consecutive trading days.  Accordingly, the Company has regained compliance with NASDAQ Listing Rule 5550(a)(2), and the matter is closed.

About China Jo-Jo Drugstores, Inc.

China Jo-Jo Drugstores, Inc., through its subsidiaries and contractually controlled affiliates, is a retailer and wholesale distributor of pharmaceutical and other healthcare products in the People’s Republic of China. As of September 30, 2012, the Company has 65 retail pharmacies throughout Zhejiang Province and Shanghai.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as “believe,” “expect,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

Contacts

China Jo-Jo Drugstores, Inc.


Ming Zhao

Chief Financial Officer


Tel: (561) 372-5555


Email: frank.zhao@jojodrugstores.com